FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA Faces Hard Decisions After Fast-Tracking Unproven Drugs

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's accelerated drug approvals often lack confirmatory evidence

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

Pristiq: Side effects and what to do about them

FDA rushes approval of dementia drug that quadruples risk of death

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA fast-tracking approval of new drugs — fewer trials, less info

SEC Filing Vistagen Therapeutics, Inc

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug

FDA fast-tracking approval of new drugs — fewer trials, less info